Gilead Sciences (GILD) Finished Goods (2009 - 2015)
Gilead Sciences (GILD) posted Finished Goods of $852.0 million for Q4 2015, up 82.83% quarter-over-quarter from $466.0 million in Q4 2014, and up 82.83% year-on-year from $466.0 million in Q4 2014.
Gilead Sciences (GILD) Finished Goods (2009 - 2015) Analysis & Trends
Gilead Sciences (GILD) has reported Finished Goods for 7 consecutive years, with $852.0 million the latest figure, recorded in Q4 2015.
- Finished Goods for Q4 2015 came in at $852.0 million, up 82.83% year-over-year; the trailing twelve-month figure through Dec 2015 was $852.0 million (up 82.83% YoY), and the FY2015 annual result was $852.0 million, up 82.83% from the prior year.
- Finished Goods was $852.0 million for Q4 2015 at Gilead Sciences, up from $466.0 million in the prior quarter.
- Over five years, Finished Goods peaked at $852.0 million in Q4 2015 and troughed at $225.9 million in Q4 2011.
- Average Finished Goods over 5 years is $487.3 million, with a median of $466.0 million recorded in 2014.
- Year-over-year, Finished Goods tumbled 33.79% in 2011 and soared 147.9% in 2012.
- Over 5 years, Finished Goods stood at $225.9 million in 2011, then jumped by 147.9% to $559.9 million in 2012, then advanced by 5.99% to $593.4 million in 2013, then dropped by 21.47% to $466.0 million in 2014, then soared by 82.83% to $852.0 million in 2015.
- Per Business Quant data, the three most recent Finished Goods figures were $852.0 million in Q4 2015, $466.0 million in Q4 2014, and $560.0 million in Q2 2014.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 852.00 Mn |
| Dec 31, 2014 | 466.00 Mn |
| Jun 30, 2014 | 559.98 Mn |
| Dec 31, 2013 | 593.44 Mn |
| Dec 31, 2012 | 559.91 Mn |
| Dec 31, 2011 | 225.86 Mn |
| Sep 30, 2011 | 295.79 Mn |
| Jun 30, 2011 | 384.72 Mn |
| Mar 31, 2011 | 448.43 Mn |
| Dec 31, 2010 | 341.14 Mn |
| Sep 30, 2010 | 439.32 Mn |
| Dec 31, 2009 | 326.15 Mn |